Depression — Clinical Documentation Guide (2026)

🔍 Definition

Major Depressive Disorder (MDD) is a common, serious, and treatable mental health condition characterized by persistent depressed mood or loss of interest/pleasure (anhedonia) that causes significant impairment in social, occupational, or other domains of functioning. MDD is classified under the DSM-5-TR as a unipolar mood disorder, distinct from bipolar and related disorders (F31.x). According to USPSTF 2023 guidance, the 12-month prevalence of MDD in U.S. adults is approximately 10% and lifetime prevalence approaches 20%, making it one of the most frequently encountered diagnoses in both primary care and behavioral health settings.

For coding purposes, depression maps primarily to the ICD-10-CM categories F32 (single episode), F33 (recurrent), and related codes including F34.1 (persistent depressive disorder/dysthymia), F34.81 (disruptive mood dysregulation disorder), F53.x (perinatal depression), and F06.31–F06.32 (mood disorder due to known physiological condition). Precise documentation of episode type, severity, recurrence, and specifiers is critical for risk adjustment under the CMS-HCC Model V28, where only moderate and severe MDD generate payment HCC credit.

🗂️ Alternative Terminology

Clinical staff and patients use a wide range of terms that may correspond to a codeable depressive disorder. CDI specialists should flag these terms in documentation and query for diagnostic specificity.

🩺 Signs & Symptoms

DSM-5-TR requires at least five of the following nine symptoms during the same two-week period, with at least one being depressed mood or anhedonia, to meet criteria for a Major Depressive Episode. These criteria directly inform ICD-10-CM severity coding and PHQ-9 scoring (Kroenke et al., 2001):

• Depressed mood most of the day, nearly every day (subjective report or observation)
• Anhedonia — markedly diminished interest or pleasure in all, or almost all, activities
• Weight/appetite change — significant weight loss or gain (≥5% in one month), or decreased/increased appetite
• Sleep disturbance — insomnia or hypersomnia nearly every day
• Psychomotor agitation or retardation observable by others (not merely subjective feelings)
• Fatigue or loss of energy nearly every day
• Feelings of worthlessness or excessive/inappropriate guilt
• Cognitive impairment — diminished ability to think, concentrate, or make decisions
• Suicidal ideation — recurrent thoughts of death, suicidal ideation, or suicide attempt

PHQ-9 Severity Mapping (aligned with ICD-10-CM severity codes):

Additional clinical indicators beyond PHQ-9: suicidal ideation or behavior (code separately as R45.851 — suicidal ideations), psychotic features (delusions, hallucinations — upgrades severity to F32.3/F33.3), presence of peripartum onset, seasonal pattern, catatonic features, anxious distress specifier, and mixed features (review bipolar exclusion under F31.x Excludes1).

🧭 Differential Diagnosis

Accurate depression coding requires ruling out or separately coding the following conditions, several of which carry distinct ICD-10-CM codes and different HCC implications:

📋 Clinical Indicators for Coders/CDI

The following documentation elements in the medical record support assignment of a specific, HCC-eligible depression code. CDI should proactively query when these indicators are present without a corresponding documented diagnosis or without adequate specificity.

🦴 Anatomy & Pathophysiology

Depression is a neurobiological disorder involving multiple intersecting systems. Key pathophysiological mechanisms relevant to clinical documentation and CDI include:

Monoamine Hypothesis: The foundational model proposes that MDD results from deficient serotonergic (5-HT), noradrenergic (NE), and dopaminergic neurotransmission. This underpins the mechanism of action of SSRIs, SNRIs, and TCAs. While oversimplified, this model remains clinically relevant because antidepressant classes target different monoamine pathways, and documentation of medication history (and prior medication failures) supports TRD coding and Spravato medical necessity.

Glutamate / NMDA Receptor Pathway: Ketamine and esketamine (Spravato) act as NMDA receptor antagonists, producing rapid antidepressant effects within hours — contrasting with the 2–6 week onset of monoamine-targeting agents. This pathway is now central to TRD treatment and relevant to documenting treatment history for prior authorization and coding justification.

HPA Axis Dysregulation: Chronic stress activates the hypothalamic-pituitary-adrenal axis, elevating cortisol. Hypercortisolism is documented in MDD and is directly relevant when depression is secondary to a medical condition (e.g., Cushing disease, corticosteroid therapy — document as F06.31/F06.32 rather than primary F32.x).

Neuroinflammation and Neuroplasticity: Inflammatory cytokines (IL-6, TNF-α, CRP) are elevated in MDD and are associated with treatment resistance. Conditions such as autoimmune disease, metabolic syndrome, and chronic pain frequently co-occur with depression, requiring concurrent coding of all documented comorbidities.

Genetic and Epigenetic Factors: First-degree relatives of MDD patients have 2–3× elevated lifetime risk. Family history (Z81.8) is a relevant additional code and supports medical necessity documentation for enhanced screening (G0444) and preventive services.

💊 Medication Impact / Treatment

Documentation of pharmacotherapy is essential for CDI, coding specificity, and HCC capture. The following agents are commonly prescribed for MDD and have specific documentation implications:

First-Line Pharmacotherapy:

• SSRIs (fluoxetine, sertraline, escitalopram, citalopram, paroxetine, fluvoxamine): First-line for most MDD episodes. Presence on medication list is a strong clinical indicator of active depression diagnosis.
• SNRIs (venlafaxine, desvenlafaxine, duloxetine, levomilnacipran): Dual serotonin-norepinephrine reuptake inhibition; frequently used in depression with comorbid pain or anxiety.
• Atypicals:
  • Bupropion (Wellbutrin): Dopamine/norepinephrine reuptake inhibitor; preferred when sexual dysfunction or weight gain are concerns.
  • Mirtazapine (Remeron): Noradrenergic and specific serotonergic antidepressant (NaSSA); useful in elderly patients with insomnia/weight loss.
  • Vortioxetine (Trintellix): Multimodal serotonergic agent with cognitive benefit claims.

Second-Line and Augmentation:

• TCAs (amitriptyline, nortriptyline, imipramine): Older class; now mainly used for TRD augmentation or comorbid pain/insomnia. Narrow therapeutic index — toxicity monitoring relevant.
• MAOIs (phenelzine, tranylcypromine, selegiline patch): Reserved for atypical depression or TRD; dietary tyramine restrictions and drug interactions are critical documentation considerations.
• Lithium augmentation: Used in TRD; requires monitoring of serum levels, renal function, thyroid function — all coworthy comorbidities.
• Atypical antipsychotic augmentation (aripiprazole, quetiapine, brexpiprazole): FDA-approved adjuncts for MDD; relevant for documenting treatment complexity and severity.

Ketamine/Esketamine (TRD):

Esketamine (Spravato), an intranasal NMDA receptor antagonist, received FDA approval in March 2019 for TRD and for MDD with acute suicidal ideation. Treatment-resistant depression is defined operationally as failure of ≥2 adequate antidepressant trials in the current episode. There is no dedicated ICD-10-CM code for TRD — document and code the specific MDD code (F32.1, F32.2, F33.1, F33.2) that reflects current severity. HCPCS code J0013 is used to bill esketamine nasal spray (per mg). Documentation must include prior medication failures, current severity, and monitoring for dissociation/blood pressure elevation per REMS requirements.

Neuromodulation:

• Electroconvulsive Therapy (ECT): Most effective acute treatment for severe or psychotic MDD; relevant in inpatient DRG 876 (O.R. procedure with mental illness). Coded with CPT 90870 and ICD-10-PCS procedure codes.
• Transcranial Magnetic Stimulation (TMS): FDA-cleared for MDD; CPT 90867–90869; typically outpatient, covered by most commercial payers and Medicare for TRD.

Drug-Induced and Medical-Condition-Related Depression:

Several medications and medical conditions can precipitate depression requiring distinct coding:

• Corticosteroids (prednisone, methylprednisolone): Well-documented cause of mood disturbance — document as adverse effect (T38.0x5A) + F06.31 or F06.32 if physiological mechanism is documented by the treating provider.
• Interferon-alpha (used for HCV, certain malignancies): High rate of depression; code as adverse effect of T45.1x5A + F06.3x.
• Beta-blockers, isotretinoin, hormonal contraceptives: Associated with mood symptoms; provider documentation of causal relationship required before coding F06.3x.
• Medical conditions (hypothyroidism E03.x, Parkinson’s disease G20.x, post-stroke F06.32, Huntington’s disease G10, Alzheimer’s G30.x): When the provider documents that the depression is a direct physiological consequence, assign F06.31 or F06.32 as the mood disorder code, plus the underlying medical condition.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO CDG members.

📘 ICD-10-CM Guidelines (FY2026)

The following ICD-10-CM Official Guidelines for Coding and Reporting, FY2026 (NCHS/CMS, effective October 1, 2025), apply to depressive disorders:

Section I.C.5 — Mental, Behavioral, and Neurodevelopmental Disorders:

• Code to the highest degree of specificity documented in the medical record by the treating provider. For depression, this means documenting episode type (single vs. recurrent), severity (mild/moderate/severe), and specifiers (with or without psychotic features, remission status).
• When the provider documents “depression” or “depressive disorder” without additional specificity, coders should assign the most appropriate unspecified code (F32.9 or F32.A). However, these unspecified codes do NOT map to a payment HCC under CMS-HCC V28 and CDI query is warranted.
• F32.A (Depression, unspecified) was added as a distinct code to capture depressive disorder NOS and depressive disorder not otherwise specified, separating it from F32.9 (MDD, single episode, unspecified). F32.A should be used when depressive symptoms are present but do not meet full MDD criteria or when the provider explicitly documents “depression NOS” or “depressive disorder NOS” without specifying an episode pattern.
• F32.9 applies when an MDD single episode is documented but severity is not specified. Both F32.9 and F32.A are non-HCC codes under V28.

Excludes Notes — Critical for Depression:

• Excludes1 (F32.x and F33.x): Bipolar disorder (F31.–) and manic episode (F30.–). These conditions cannot be coded together with F32.x/F33.x. If documentation supports both, query the provider for clarification.
• Excludes2 (F32.x): Adjustment disorder (F43.2–). If adjustment disorder is the appropriate diagnosis, it can still be coded if co-occurring with depression, but the conditions are clinically distinct.
• F34.1 (Persistent Depressive Disorder / Dysthymia) and F34.81 (Disruptive Mood Dysregulation Disorder) are separate categories; neither maps to HCC 155 under CMS-HCC V28 as of FY2026.

Perinatal Depression (F53.x):

• F53.0 (Postpartum depression) is used specifically for depression occurring within the postpartum period (generally up to 12 months following delivery) not classified under the O chapter. Do not code F32.x for postpartum depression — use F53.0.
• F53.1 (Puerperal psychosis) for psychotic episodes in the postpartum period.
• Prenatal/antepartum depression: Refer to O99.340–O99.345 (mental disorders complicating pregnancy) from the obstetric chapter when applicable during pregnancy.

Depression Screening (Z13.31):

Per USPSTF 2023 Grade B recommendation, universal screening for depression is recommended for all adults ≥18, including pregnant/postpartum persons and older adults ≥65. Assign Z13.31 (Encounter for screening for depression) as the primary diagnosis code for a screening-only encounter. If the screening is positive and the provider diagnoses MDD at the same encounter, code both the screening Z code and the appropriate depression code.

Mood Disorders Due to Known Physiological Condition:

• F06.31 — Mood disorder due to known physiological condition with depressive features (does not meet full MDD criteria)
• F06.32 — Mood disorder due to known physiological condition with major depressive-like episode (meets MDD criteria but is secondary to a physiological cause)
• Code also the underlying physiological condition first if indicated by sequencing rules
• Excludes2: Mood disorders due to alcohol and other psychoactive substances (F10–F19 with .14, .24, .94)

🔢 ICD-10-CM Code Set (FY2026)

🔎 Indexing

Use the ICD-10-CM Alphabetic Index to verify code selection. Key index entries for depression include:

• Depression (acute) (mental) → see also Disorder, depressive F32.9
• Disorder, depressive
  • major, single episode → see codes F32.0–F32.9, F32.A
  • recurrent → F33.0–F33.9
  • persistent → F34.1
  • due to known physiological condition → F06.3x
  • postpartum → F53.0
• Dysthymia → F34.1
• Depression, postpartum → F53.0
• Mood disorder due to physiological condition → F06.3x (with depressive features F06.31; with major depressive-like episode F06.32)
• Disorder, disruptive mood dysregulation → F34.81
• Ideation, suicidal → R45.851
• Screening, depression → Z13.31

Tabular Verification Notes: Always confirm in the Tabular List that the final digit is valid for FY2026. F32.A uses the letter “A” as the final character — this is a valid alphanumeric extension in ICD-10-CM. F33.9 maps to recurrent MDD unspecified; some payer-specific RAF tools (e.g., ChenMed V28 handout) note F33.9 under HCC 155 in certain contexts, but CMS official crosswalk should be confirmed for the payment year.

🏥 CPT (2026)

The following CPT codes apply to evaluation, management, screening, psychotherapy, and collaborative care for depressive disorders. All CPT codes and descriptions are proprietary to the American Medical Association (AMA).

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic guidance is relevant to depression coding. Always reference the current edition for the most up-to-date official advice:

• Suicidal Ideation as Additional Code: Coding Clinic has consistently confirmed that suicidal ideation (R45.851) is NOT inherent to a depression diagnosis and should be coded additionally when documented by the provider. This applies in both inpatient and outpatient settings.
• Depression with Psychotic Features: When a provider documents “psychotic depression” or “depression with hallucinations/delusions,” Coding Clinic supports assignment of F32.3 or F33.3. If the psychotic features are separately documented and managed, review whether an additional psychosis code is appropriate per current edition guidance.
• Postpartum vs. General Depression: Coding Clinic has clarified that postpartum depression occurring within the postpartum period should be coded F53.0, not F32.x. The O chapter codes (O99.340–O99.345) apply during the antepartum period in conjunction with the relevant F-code.
• F32.A — Depression, Unspecified (New Code): This code captures “Depression NOS” and “Depressive disorder NOS,” distinguishing it from F32.9 (MDD single episode, unspecified). Providers should be educated that using “depression NOS” documentation will result in a non-HCC, non-specificity code, limiting risk adjustment capture.
• Secondary Depression (F06.31/F06.32): Coding Clinic guidance supports using these codes when the treating provider explicitly documents that the depression is physiologically caused by the underlying medical condition. Documentation of the causal relationship — not merely co-occurrence — is required.
• Seasonal Affective Disorder: Coded as F33.x (recurrent MDD) with the seasonal pattern specifier documented in the clinical note; there is no separate ICD-10-CM code for SAD.

💰 HCC / Risk Adjustment (V28)

Under the CMS-HCC Model V28, fully operative for payment year 2026 (100% V28 phase-in complete), depression coding has undergone significant restructuring from the prior V24 model. Understanding these changes is essential for Medicare Advantage plan coders, CDI specialists, and risk adjustment professionals.

V28 Key Changes from V24 for Depression:

• V24 mapped MDD to HCC 59 (“Major Depressive, Bipolar, and Paranoid Disorders”) — a broader category that included mild and remission codes.
• V28 created HCC 155 specifically for “Major Depression, Moderate or Severe, without Psychosis,” with a coefficient of approximately 0.299 for community, non-dual, aged beneficiaries, per Patient Quality Alliance V28 Tip Sheet.
• Mild depression (F32.0, F33.0), remission codes (F32.4, F32.5, F33.4x), and unspecified codes (F32.9, F32.A, F33.9) were removed from the payment HCC model under V28, per RAAPID V28 analysis and AAFP V28 physician update.
• The CMS 2027 Advance Notice proposes a further -13.7% coefficient reduction for Major Depression HCCs, signaling continued tightening of depression risk adjustment.

✍️ CDI Query Templates

All query language follows ACDIS/AHIMA compliant query standards — non-leading, clinically grounded, offering multiple-choice options including “other” and “unable to determine.”

🧑‍⚕️ Treatments (Clinical)

Evidence-based treatments for Major Depressive Disorder span pharmacotherapy, psychotherapy, neuromodulation, and collaborative care models. Documenting the treatment plan is essential for medical necessity, coding, and risk adjustment purposes.

Psychotherapy:

• Cognitive Behavioral Therapy (CBT): Strongest evidence base for MDD; typically 12–20 sessions; time-based CPT 90832–90837.
• Interpersonal Therapy (IPT): Particularly effective for perinatal depression and MDD with interpersonal stressors; 12–16 sessions.
• Behavioral Activation (BA): Component of CBT; increasing engagement with rewarding activities; effective for all severity levels.
• Psychodynamic Therapy: Longer-term approach; evidence base for MDD, particularly with comorbid personality pathology.

Pharmacotherapy (First-Line to Third-Line): As described in Section 7 above. The APA 2024 Clinical Practice Guideline for Major Depressive Disorder recommends shared decision-making in selecting antidepressant agents, with consideration of side effect profiles, patient preferences, and comorbidities. Duration of maintenance therapy: 6–12 months after first episode remission; indefinite maintenance considered after 2+ episodes or severe/psychotic episodes.

Neuromodulation:

• ECT: Gold standard for severe, psychotic, or medication-refractory MDD; rapid response in 2–4 weeks; 6–12 acute treatments; relevant for MS-DRG 876 inpatient billing.
• TMS (rTMS): 20–40 sessions outpatient; FDA-cleared for TRD; CPT 90867–90869; covered by Medicare for TRD per CMS LCD L36469.
• Esketamine (Spravato): Rapid-acting for TRD and MDD with acute suicidal ideation; REMS program; administered in certified healthcare settings only; HCPCS J0013.
• Ketamine IV infusions: Not FDA-approved for depression but used off-label; no specific HCPCS; typically billed as miscellaneous drug code J3490 or facility infusion codes.

Collaborative Care Model (CoCM):

The AIMS Center Collaborative Care Model is a team-based approach integrating a behavioral health care manager, consulting psychiatrist, and primary care provider, with population-based registry tracking and treat-to-target protocols. Billing via CPT 99492/99493/99494 and HCPCS G2214 (Medicare). The USPSTF and CMS recognize CoCM as an evidence-based approach for depression in primary care settings.

Inpatient Treatment — MS-DRG Considerations:

• MS-DRG 880 — Acute Adjustment Reaction and Psychosocial Dysfunction
• MS-DRG 881 — Depressive Neuroses (includes MDD admissions without major procedures)
• MS-DRG 885 — Psychoses (when psychotic features are principal diagnosis or define the DRG)
• MS-DRG 876 — O.R. Procedures with Principal Diagnosis of Mental Illness (ECT, etc.)
• Principal diagnosis selection in inpatient psychiatric admissions follows UHDDS and Uniform Hospital Discharge Data Set guidelines — the condition chiefly responsible for admission after study.

🎓 Patient Education / Summary

The following patient-facing summary may be used by care coordinators, social workers, and discharge educators to reinforce understanding of depression diagnosis and treatment:

What is Depression?
Depression (also called Major Depressive Disorder) is a medical condition that affects how you feel, think, and handle daily activities. It is not a character flaw or weakness — it is a treatable illness that involves real changes in brain chemistry. According to the USPSTF, depression affects about 1 in 10 adults each year.

Common symptoms include: persistent sadness or emptiness, loss of interest in activities you used to enjoy, changes in sleep or appetite, fatigue, difficulty concentrating, feelings of worthlessness, and in severe cases, thoughts of death or suicide. If you are having thoughts of suicide, contact the 988 Suicide & Crisis Lifeline by calling or texting 988.

Screening and Diagnosis:
Your doctor may ask you to complete a brief questionnaire called the PHQ-9 to assess your mood. This 9-question tool helps identify the severity of depression and guides treatment decisions. According to the USPSTF 2023 guidelines, screening for depression is recommended for all adults, including during and after pregnancy.

Treatment Options:
Effective treatments include:

• Medications: Antidepressants (SSRIs, SNRIs, and others) are generally safe and effective. It may take 4–8 weeks to feel the full benefit. Do not stop medication without talking to your provider.
• Therapy (Counseling): Talk therapies like Cognitive Behavioral Therapy (CBT) teach coping skills and have been proven highly effective.
• Combined therapy and medication is often more effective than either alone for moderate to severe depression.
• Advanced treatments: For severe or treatment-resistant depression, options include TMS (Transcranial Magnetic Stimulation), ECT (Electroconvulsive Therapy), and esketamine (Spravato) nasal spray — all administered under medical supervision.

Important for Your Medical Record:
Accurate documentation of your depression — including how severe it is, whether it is a first episode or a return of symptoms, and whether you have psychotic symptoms — helps your care team code your diagnosis correctly. Correct diagnosis coding matters for your insurance coverage, access to specialized treatments, and continuity of care. If your provider has asked you about the severity of your depression, it is to ensure you receive the right level of care and that your treatment is properly documented.

Resources:

• American Psychiatric Association — Depression Resources
• NIMH — Depression Overview
• USPSTF Depression Screening Recommendation
• 988 Suicide & Crisis Lifeline: Call or text 988

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)